16 analysts have shared their evaluations of Tenet Healthcare THC during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 4 | 5 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $184.56, with a high estimate of $217.00 and a low estimate of $140.00. A 0.2% drop is evident in the current average compared to the previous average price target of $184.93.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst actions sheds light on the perception of Tenet Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tim Rezvan | Keybanc | Lowers | Overweight | $185.00 | $200.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $175.00 | $190.00 |
| Benjamin Rossi | JP Morgan | Announces | Overweight | $175.00 | - |
| Jamie Perse | Goldman Sachs | Lowers | Neutral | $140.00 | $196.00 |
| Stephen Baxter | Wells Fargo | Lowers | Equal-Weight | $150.00 | $205.00 |
| John Ransom | Raymond James | Maintains | Outperform | $195.00 | $195.00 |
| Andrew Mok | Barclays | Raises | Overweight | $190.00 | $171.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $205.00 | $195.00 |
| Sarah James | Cantor Fitzgerald | Raises | Overweight | $177.00 | $168.00 |
| Jamie Perse | Goldman Sachs | Raises | Buy | $196.00 | $173.00 |
| Ben Hendrix | RBC Capital | Raises | Outperform | $183.00 | $174.00 |
| David Macdonald | Truist Securities | Raises | Buy | $190.00 | $180.00 |
| A.J. Rice | UBS | Raises | Buy | $217.00 | $197.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $195.00 | $175.00 |
| David Macdonald | Truist Securities | Raises | Buy | $180.00 | $170.00 |
| Matthew Gillmor | Keybanc | Announces | Overweight | $200.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Tenet Healthcare analyst ratings.
Discovering Tenet Healthcare: A Closer Look
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Tenet Healthcare's Financial Performance
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Tenet Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.11%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 12.92%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 3.36, Tenet Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
